Tyrosine kinase

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Entospletinib, Indazoles, Morpholines, Tyrosine-protein kinase SYK, Enzymes, Acute myeloid leukemia, Tyrosine kinase, NPM1, Protein kinase inhibitors

A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.

Key Points: 
  • A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • For more information, visit www.kronosbio.com or follow the company on LinkedIn .\n'

Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

Retrieved on: 
Wednesday, April 28, 2021
Tyrosine kinase receptors, Branches of biology, ErbB, Receptor tyrosine kinase, Tyrosine kinase, Trk receptor

BDTX-189 is designed as a MasterKey inhibitor targeting a family of previously undrugged and functionally similar oncogenic mutations in a tumor-agnostic manner.

Key Points: 
  • BDTX-189 is designed as a MasterKey inhibitor targeting a family of previously undrugged and functionally similar oncogenic mutations in a tumor-agnostic manner.
  • The ErbB receptors are a group of receptor tyrosine kinases involved in key cellular functions, including cell growth and survival.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
  • Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .\n'

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

Retrieved on: 
Wednesday, April 28, 2021
Drugs, Tyrosine kinase inhibitors, Fostamatinib, Organophosphates, Prodrugs, Tyrosine kinases, Tyrosine-protein kinase SYK, Enzymes, Tyrosine kinase, Cerdulatinib

b"SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ --Rigel Pharmaceuticals,Inc.

Key Points: 
  • b"SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ --Rigel Pharmaceuticals,Inc.
  • (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021.
  • Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms.
  • The company's first FDA approved product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Retrieved on: 
Tuesday, March 30, 2021
Tyrosine kinase receptors, Branches of biology, Cell biology, Hepatocyte growth factor, Biology, C-Met, Tyrosine kinase, Receptor tyrosine kinase

This a very exciting time for Angion, said Dr. Jay R. Venkatesan, Angions President and Chief Executive Officer.

Key Points: 
  • This a very exciting time for Angion, said Dr. Jay R. Venkatesan, Angions President and Chief Executive Officer.
  • In 2020, we advanced the clinical development of our lead program ANG-3777, a small molecule HGF mimetic, being investigated in acute organ injuries, continued Dr. Venkatesan.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

LOU-064: An Agammaglobulinaemia Tyrosine Kinase Inhibitors Being Developed by Novartis for Sjogren's Syndrome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 25, 2021
Health, Pharmaceutical, Novartis, Pharmaceutical companies, Protein kinase inhibitor, Tyrosine kinase, Companies, Life sciences

"LOU-064 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's Syndrome in 7 Major Markets.

Key Points: 
  • "LOU-064 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's Syndrome in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • LOU-064 acts as Agammaglobulinaemia tyrosine kinase inhibitors and is being developed by Novartis for Sjogren's syndrome which is currently in Phase II of clinical trial study.
  • Other emerging products for Sjogren's Syndrome are giving market competition to LOU-064 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors

Retrieved on: 
Wednesday, March 24, 2021
Sortilin 1, Tyrosine kinase inhibitor, Tyrosine kinase, Tyrosine kinase receptors

Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer.

Key Points: 
  • Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer.
  • The U.S. Food and Drug Administration (FDA) recently granted fast track designation to TH1902 as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy.
  • TH1902 is the Companys lead PDC stemming from Theratechnologies SORT1+ Technology in oncology.
  • Commercially available anticancer drugs, like docetaxel, doxorubicin or tyrosine kinase inhibitors are conjugated to Theratechnologies investigational novel peptide to specifically target sortilin receptors.

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Tyrosine kinase receptors, Enzymes, Receptor tyrosine kinase, ErbB, Kinase, Tyrosine kinase, Epidermal growth factor receptor, Protein kinase

Both presentations will also be available online on the Companys website at https://www.blackdiamondtherapeutics.com/technology/presentations-public... .

Key Points: 
  • Both presentations will also be available online on the Companys website at https://www.blackdiamondtherapeutics.com/technology/presentations-public... .
  • The ErbB receptors are a group of receptor tyrosine kinases involved in key cellular functions, including cell growth and survival.
  • Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

Angion to Participate in Upcoming March Investment Conferences

Retrieved on: 
Wednesday, February 24, 2021
Enzymes, Aldosterone synthase, ROCK2, Rho-associated protein kinase, Tyrosine kinase, Kinase

Dr. Jay Venkatesan, Angions President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference.

Key Points: 
  • Dr. Jay Venkatesan, Angions President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference.
  • All three virtual investor conferences will take place in March 2021.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Retrieved on: 
Monday, February 22, 2021
Tyrosine kinase receptors, Clusters of differentiation, Branches of biology, Cell biology, Biology, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Fibroblast growth factor, Tyrosine kinase, Cholangiocarcinoma, Protein kinase inhibitor

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Geriatrics, Parkinson's disease, Psychiatric diagnosis, Branches of biology, Tyrosine kinase, ABL, Medical specialties, Clinical medicine, Parkinson’s Disease, Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinsons disease.

Key Points: 
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinsons disease.
  • The initiation of our Phase 1 study of IkT-148009 for the treatment of Parkinsons disease represents a significant milestone for Inhibikase.
  • C-Abl then drives biochemical pathways and processes that lead to degradation of the neurons affected in Parkinsons disease.
  • Inhibikase (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinsons disease and related disorders.